Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Florence Gattacceca"'
Autor:
Alexis Courbet, Nicole Bec, Caroline Constant, Christian Larroque, Martine Pugniere, Safia El Messaoudi, Zahraa Zghaib, Sonia Khier, Carine Deleuze-Masquefa, Florence Gattacceca
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0182022 (2017)
Displaying a strong antiproliferative activity on a wide variety of cancer cells, EAPB0203 and EAPB0503 belong to the imidazo[1,2-a]quinoxalines family of imiquimod structural analogues. EAPB0503 has been shown to inhibit tubulin polymerization. The
Externí odkaz:
https://doaj.org/article/4641e264c43e45a79d28c8192d42093a
Autor:
Alicia Probst, Emilie De Carli, Isabelle Aerts, Pascal Chastagner, Natacha Entz-Werle, Caroline Solas, Anne-Isabelle Bertozzi-Salamon, Nicolas André, Anne Pagnier, Emmanuelle Tresch-Bruneel, Pierre Leblond, Jacques Grill, Didier Frappaz, Mourad Hamimed, Florence Gattacceca
Publikováno v:
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, 2021, ⟨10.1111/bcp.15131⟩
British Journal of Clinical Pharmacology, Wiley, 2021, ⟨10.1111/bcp.15131⟩
British Journal of Clinical Pharmacology, 2021, ⟨10.1111/bcp.15131⟩
British Journal of Clinical Pharmacology, Wiley, 2021, ⟨10.1111/bcp.15131⟩
AIM There is a crucial need for pharmacokinetic (PK) data of oral vinorelbine (VNR) in pediatric population. The aim of this work was to assess the PK profile of orally administered VNR in children with recurrent/progressive primary low-grade glioma
Autor:
Florence Gattacceca, Alexandre Evrard, Marc Ychou, Laure Deyme, Dominique Barbolosi, Nicole Tubiana-Mathieu, Litaty Mbatchi
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 2021, 88 (2), pp.247-258. ⟨10.1007/s00280-021-04255-9⟩
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2021, 88 (2), pp.247-258. ⟨10.1007/s00280-021-04255-9⟩
Cancer Chemotherapy and Pharmacology, 2021, 88 (2), pp.247-258. ⟨10.1007/s00280-021-04255-9⟩
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2021, 88 (2), pp.247-258. ⟨10.1007/s00280-021-04255-9⟩
International audience; PurposeThe aim of the present study was to characterize the pharmacokinetics of irinotecan and its four main metabolites (SN-38, SN-38G, APC and NPC) in metastatic colorectal cancer patients treated with FOLFIRI and FOLFIRINOX
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics
Journal of Pharmacokinetics and Pharmacodynamics, Springer Verlag, 2020, ⟨10.1007/s10928-020-09695-z⟩
Journal of Pharmacokinetics and Pharmacodynamics, Springer Verlag, 2020, ⟨10.1007/s10928-020-09695-z⟩
Population pharmacokinetic analysis is used to estimate pharmacokinetic parameters and their variability from concentration data. Due to data sparseness issues, available datasets often do not allow the estimation of all parameters of the suitable mo
Autor:
Mourad Hamimed, Pierre Leblond, Aurélie Dumont, Florence Gattacceca, Emmanuelle Tresch-Bruneel, Alicia Probst, Pascal Chastagner, Anne Pagnier, Emilie De Carli, Natacha Entz-Werlé, Jacques Grill, Isabelle Aerts, Didier Frappaz, Anne-Isabelle Bertozzi-Salamon, Caroline Solas, Nicolas André, Joseph Ciccolini
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 2022, 90 (1), pp.29-44. ⟨10.1007/s00280-022-04446-y⟩
Cancer Chemotherapy and Pharmacology, 2022, 90 (1), pp.29-44. ⟨10.1007/s00280-022-04446-y⟩
Better understanding of pharmacokinetics of oral vinorelbine (VNR) in children would help predicting drug exposure and, beyond, clinical outcome. Here, we have characterized the population pharmacokinetics of oral VNR and studied the factors likely t
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2019, 83 (1), pp.27-42. ⟨10.1007/s00280-018-3722-5⟩
Cancer Chemotherapy and Pharmacology, 2019, 83 (1), pp.27-42. ⟨10.1007/s00280-018-3722-5⟩
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2019, 83 (1), pp.27-42. ⟨10.1007/s00280-018-3722-5⟩
Cancer Chemotherapy and Pharmacology, 2019, 83 (1), pp.27-42. ⟨10.1007/s00280-018-3722-5⟩
FOLFIRINOX regimen is commonly used in colorectal and more recently pancreatic cancer. However, FOLFIRINOX induces significant and dose-limiting toxic effects leading to empirical dose reduction and sometimes treatment discontinuation. Model-based FO
Autor:
Benoit Blanchet, Florence Gattacceca, Hai le Ba, Bruno Lacarelle, Alexandre Evrard, Joseph Ciccolini, Litaty Mbatchi, Sébastien Salas
Publikováno v:
Pharmacogenomics
Pharmacogenomics, Future Medicine, 2020, 21 (3), pp.173-179. ⟨10.2217/pgs-2019-0127⟩
Pharmacogenomics, 2020, 21 (3), pp.173-179. ⟨10.2217/pgs-2019-0127⟩
Pharmacogenomics, Future Medicine, 2020, 21 (3), pp.173-179. ⟨10.2217/pgs-2019-0127⟩
Pharmacogenomics, 2020, 21 (3), pp.173-179. ⟨10.2217/pgs-2019-0127⟩
International audience; A 53-year-old woman with papillary thyroid cancer treated with 800 mg sorafenib therapy rapidly experienced grade 3 toxicities. Dosing was reduced in a step-wise manner with several treatment discontinuations down to 200 mg ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d76344f41069237a467887e2907bff5b
https://hal.archives-ouvertes.fr/hal-03464965
https://hal.archives-ouvertes.fr/hal-03464965
Autor:
Cindy Serdjebi, Eric Francois, Bruno Lacarelle, Gael Deplanque, Joseph Ciccolini, Jean-François Seitz, Madani Rachid, Laetitia Dahan, Abakar Abakar-Mahamat, Florence Gattacceca, Johan Gagnière, Francine Fein
Publikováno v:
Therapeutic Drug Monitoring. 39:290-296
Gemcitabine remains a pillar in pancreatic cancer treatment. However, toxicities are frequently observed. Dose adjustment based on therapeutic drug monitoring might help decrease the occurrence of toxicities. In this context, this work aims at descri
Autor:
Bruno Sarmento, Florence Gattacceca, Harkiranpreet Kaur Dhaliwal, Mansoor M. Amiji, Flávia Sousa
Publikováno v:
Journal of Controlled Release
Journal of Controlled Release, 2019, 309, pp.37-47. ⟨10.1016/j.jconrel.2019.07.033⟩
Journal of Controlled Release, Elsevier, 2019, 309, pp.37-47. ⟨10.1016/j.jconrel.2019.07.033⟩
Journal of Controlled Release, 2019, 309, pp.37-47. ⟨10.1016/j.jconrel.2019.07.033⟩
Journal of Controlled Release, Elsevier, 2019, 309, pp.37-47. ⟨10.1016/j.jconrel.2019.07.033⟩
International audience; Glioblastoma multiforme (GBM) is one of the most aggressive cancers, where the aggressiveness of tumor has been associated to its high vascularization rate. Bevacizumab (Avastin®), an anti-angiogenic monoclonal antibody, has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29f4afce8bda09549a2ff0a6227d7370
https://hal.science/hal-02533340
https://hal.science/hal-02533340
Autor:
Florence Gattacceca, Nadège Néant, Caroline Solas, Gilles Peytavin, Diane Descamps, Catherine Dhiver, Yazdan Yazdanpanah, Bruno Lacarelle, Naïm Bouazza, Minh Patrick Lê, Catherine Tamalet, Saadia Mokhtari, Sylvie Bregigeon
Publikováno v:
Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2019, 74 (7), pp.1992-2002. ⟨10.1093/jac/dkz141⟩
Journal of Antimicrobial Chemotherapy, 2019, 74 (7), pp.1992-2002. ⟨10.1093/jac/dkz141⟩
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2019, 74 (7), pp.1992-2002. ⟨10.1093/jac/dkz141⟩
Journal of Antimicrobial Chemotherapy, 2019, 74 (7), pp.1992-2002. ⟨10.1093/jac/dkz141⟩
Background Rilpivirine is widely prescribed in people living with HIV. Although trough plasma concentrations have been associated with virological response, the drug pharmacodynamics remain incompletely characterized. Objectives To develop the first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a065712ddc9cdfe2d027b27f76c411ea
https://hal.archives-ouvertes.fr/hal-02530387
https://hal.archives-ouvertes.fr/hal-02530387